Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of various medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company is developing its lead antibody product candidate, SRK-015, a first-in-class inhibitor of the activation of myostatin that is in clinical development stage for the treatment of spinal muscular atrophy. It is also developing various product candidates for a range of serious diseases, including other neuromuscular disorders, cancer, fibrosis, and anemia. The company was founded in 2012 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SRRK
Previous Symbol
CUSIPN/A
Phone857-259-3860
Debt
Debt-to-Equity RatioN/A
Current Ratio18.43
Quick Ratio18.43
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$370,000.00
Price / Sales1,399.80
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees50
Outstanding Shares25,240,000
Market Cap$506.26 million
OptionableNot Optionable
Scholar Rock (NASDAQ:SRRK) Frequently Asked Questions
What is Scholar Rock's stock symbol?
Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."
When is Scholar Rock's next earnings date?
What price target have analysts set for SRRK?
4 analysts have issued 1-year target prices for Scholar Rock's shares. Their predictions range from $25.00 to $31.00. On average, they anticipate Scholar Rock's stock price to reach $27.3333 in the next twelve months. This suggests a possible upside of 33.2% from the stock's current price. View Analyst Price Targets for Scholar Rock.
What is the consensus analysts' recommendation for Scholar Rock?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Scholar Rock.
Has Scholar Rock been receiving favorable news coverage?
Media headlines about SRRK stock have trended neutral recently, InfoTrie reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Scholar Rock earned a news sentiment score of 0.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term.
Are investors shorting Scholar Rock?
Scholar Rock saw a decline in short interest during the month of October. As of October 15th, there was short interest totalling 664,357 shares, a decline of 35.6% from the September 28th total of 1,031,955 shares. Based on an average trading volume of 54,558 shares, the short-interest ratio is presently 12.2 days. Currently, 4.6% of the shares of the company are short sold. View Scholar Rock's Current Options Chain.
Who are some of Scholar Rock's key competitors?
Some companies that are related to Scholar Rock include Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA), Rubius Therapeutics (RUBY), Orchard Therapeutics (ORTX), Spark Therapeutics (ONCE), Editas Medicine (EDIT), Autolus Therapeutics (AUTL), Solid Biosciences (SLDB), Iovance Biotherapeutics (IOVA), Sangamo Therapeutics (SGMO), Momenta Pharmaceuticals (MNTA), Audentes Therapeutics (BOLD) and DBV TECHNOLOGIE/S (DBVT).
Who are Scholar Rock's key executives?
Scholar Rock's management team includes the folowing people:
- Mr. Nagesh K. Mahanthappa Ph.D., Pres, CEO & Exec. Director (Age 53)
- Mr. Elan Z. Ezickson, COO & Head of Corp. Devel. (Age 54)
- Mr. Yung H. Chyung, Chief Medical Officer (Age 42)
- Ms. Rhonda M. Chicko, Chief Financial Officer (Age 52)
- Mr. Alan J. Buckler, Chief Scientific Officer (Age 58)
When did Scholar Rock IPO?
(SRRK) raised $76 million in an IPO on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
When did Scholar Rock's lock-up period expire?
Scholar Rock's lock-up period expired on Tuesday, November 20th. Scholar Rock had issued 5,360,000 shares in its initial public offering on May 24th. The total size of the offering was $75,040,000 based on an initial share price of $14.00. Since the expiration of Scholar Rock's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.
Who are Scholar Rock's major shareholders?
Scholar Rock's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include EcoR1 Capital LLC (9.38%), Redmile Group LLC (7.02%), BlackRock Inc. (1.46%), Sphera Funds Management LTD. (1.18%), BB Biotech AG (0.75%) and Victory Capital Management Inc. (0.36%). Company insiders that own Scholar Rock stock include Amir Nashat and International SCA Artal. View Institutional Ownership Trends for Scholar Rock.
Which major investors are selling Scholar Rock stock?
Which major investors are buying Scholar Rock stock?
SRRK stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., BB Biotech AG, Redmile Group LLC, Bank of New York Mellon Corp, Sphera Funds Management LTD., TIAA CREF Investment Management LLC, Harel Insurance Investments & Financial Services Ltd. and Teachers Advisors LLC. Company insiders that have bought Scholar Rock stock in the last two years include Amir Nashat and International SCA Artal. View Insider Buying and Selling for Scholar Rock.
How do I buy shares of Scholar Rock?
Shares of SRRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Scholar Rock's stock price today?
One share of SRRK stock can currently be purchased for approximately $20.52.
How big of a company is Scholar Rock?
Scholar Rock has a market capitalization of $506.26 million and generates $370,000.00 in revenue each year. Scholar Rock employs 50 workers across the globe.
What is Scholar Rock's official website?
How can I contact Scholar Rock?
Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3860 or via email at [email protected]
MarketBeat Community Rating for Scholar Rock (NASDAQ SRRK)
MarketBeat's community ratings are surveys of what our community members think about Scholar Rock and other stocks. Vote "Outperform" if you believe SRRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRRK will underperform the S&P 500 over the long term. You may vote once every thirty days.
